your badges 52W Range $7–$17 52% of range Analyst Rating STRONG BUY 7 analysts Price Target $19 +54% upside P/E 105.7 ROE 11.2% Net Profit Margin 14.5%

BWAY Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range

03
Price $12.50
P/E 105.7
EPS $0.18
Revenue $52M
ROE 11.2%
52W Range $7–$17

BWAY Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view

04
range
bars

Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.

Stock splits 2
Ex-date Split Type
March 4, 2026 2-for-1 Forward
March 3, 2026 2-for-1 Forward

About BrainsWay Ltd. - American Depositary Shares Company overview from Wikipedia

05 · wikidata

BrainsWay Ltd. (Hebrew: בריינסוויי) is an international company that is engaged in the development of a medical device that uses H-coil for deep transcranial magnetic stimulation (Deep TMS) as a non-invasive treatment for depression, OCD, and smoking addiction. The company was founded in 2003 and has offices in the US and Jerusalem.

## History

The magnetic coil technology used by BrainsWay's devices, called the "H coil", emerged from research done in the late 1990s and early 2000s at the U.S. National Institutes of Health (NIH) by Abraham Zangen, Roy A. Wise, Mark Hallett, Pedro C. Miranda and Yiftach Roth. Most coils used in transcranial magnetic stimulation (TMS) provide a shallow magnetic field that affects neurons mostly on the surface of the brain, delivered with coil shaped like the number eight. The H coil provided magnetic fields deeper in the brain, and devices using them provide what is called "deep TMS".

The H-coil was patented by the NIH in 2002, and the procedure whereby the H-coil was applied to TMS became known as Deep TMS.

BrainsWay was founded in 2003 in Delaware by Uzi Sofer and Avner Hagai, together with David Zacut, and they set up a subsidiary in Jerusalem, and obtained an exclusive license from the NIH for the patent it filed on the H coil. By 2006 the company had conducted animal studies at Weizmann Institute of Science and had run its first clinical trial assessing safety, at Tel Aviv University.

In early 2007 BrainsWay executed an initial public offering on the Tel Aviv Stock Exchange, raising ₪33 million for a market cap of ₪110 million. In 2010 BrainsWay announced plans to list shares of the company's stock on the Nasdaq exchange but withdrew them in June.

In January 2013, BrainsWay received clearance from the U.S. Food and Drug Administration and from Health Canada to market its deep TMS device in the United States and in Canada as a treatment for treatment-resistant major depressive disorder. Evidence to support this use is tentative; as of 2013 no high quality evidence is available.

In August 2020, BrainsWay received FDA clearance for its deep TMS device for use in smoking addiction. The device has also previously been cleared by the FDA using an H1-coil for major depressive disorder and H7-coil for OCD.

In September 2025, BrainsWay received FDA clearance for an accelerated MDD protocol that shortens the initial treatment phase from 4 weeks down to just 6 days.

Source: Wikipedia, CC BY-SA 4.0 · View on Wikipedia ↗

Wikidata ↗

sectorHealth Care industryHealth Care employees129 countryIL

10-Year Performance Revenue, net income, margins and EPS trends

06
Revenue$52M
2017-12-31 → 2025-12-31
EPS$0.18
2021-12-31 → 2025-12-31
Free Cash Flow·
2019-12-31 → 2021-12-31
Net margin14.5%
2019-12-31 → 2025-12-31
Valuation & Ratios 07–12

Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?

Metric 5Y trend BWAY 5Y avg Peer Median Verdict
P/E 105.75Y avg ≈40.3 ≈40.3 · ·

Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.

value · ≈ 5Y avg · industry median · verdict relative to median

Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date

14
Avg Surprise 66.2%
PeriodReportEPS ActualEPS EstSurprise
June 30, 2026 $0.21 $0.15 36.5%
March 31, 2026 $0.19 $0.17 7.0%
Dec. 31, 2025 $0.26 $0.13 98.0%
Sept. 30, 2025 $0.13 $0.10 35.6%
June 30, 2025 $0.18 $0.09 95.2%
March 31, 2025 $0.26 $0.13 98.0%
Dec. 31, 2024 $0.15 $0.08 93.2%

Full Fundamentals All metrics by year — income statement, balance sheet, cash flow

15
Income Statement 15
Metric Trend 20252024202320222021202020192018
Revenue $52M$41M$32M$27M$30M$22M$23M$16M
Cost of Revenue $13M$10M$8M$7M$7M$5M$5M$4M
Gross Profit $39M$31M$23M$20M$23M$17M$18M$13M
R&D Expense $10M$7M$7M$8M$6M$6M$8M$6M
SG&A Expense $7M$6M$5M$7M$6M$5M$5M$3M
Operating Income $4M$1M$-5M$-13M$-5M$-5M$-8M$-5M
Interest Expense $2M$2M$1M$1M$-2M$319.0K$1M$1M
Interest Income $6M$4M$2M$1M$255.0K···
Pretax Income $8M$3M$-4M$-13M$-6M$-5M$-10M$-6M
Income Tax $135.0K$538.0K$251.0K$315.0K$43.0K$237.0K$422.0K$209.0K
Net Income $8M$3M$-4M$-13M$-6M$-5M$-10M$-6M
EPS (Basic) $0.20$0.09$-0.13$-0.40$-0.21···
EPS (Diluted) $0.18$0.05$-0.13$-0.40$-0.21···
Shares (Basic) 38,005,25133,969,07733,155,66932,980,99731,154,25822,453,02520,506,20216,640,446
EBITDA $4M$1M$-5M$-13M$-5M$-5M$-8M·
Balance Sheet 9
Metric Trend 20252024202320222021202020192018
Cash & Equivalents $68M$69M$35M$48M$17M$17M$22M$9M
Inventory $7M$4M$4M$4M····
Current Assets $84M$80M$55M$58M$65M$24M$29M$13M
PP&E (Net) ·····$4M$4M$3M
Total Assets $113M$94M$63M$64M$76M$34M$39M$24M
Accounts Payable $7M$6M$5M$4M$5M$4M$3M$3M
Current Liabilities $22M$15M$10M$8M$9M$7M$7M$8M
Retained Earnings $-91M$-98M$-101M$-97M$-84M$-77M$-72M$-62M
Stockholders' Equity $73M$62M$42M$45M$57M$20M$24M$7M
Cash Flow 6
Metric Trend 20252024202320222021202020192018
Operating Cash Flow $17M$10M$1M$-10M$884.0K$-1M$-7M$-4M
CapEx ····$2M$2M$3M$2M
Investing Cash Flow $-17M$30M$-37M$42M$-42M$-2M$-2M$-1M
Financing Cash Flow $-2M$18M$-1M$-2M$42M$-1M$22M$-265.0K
Free Cash Flow ····$-1M$-4M$-11M·
Levered FCF ····$-3M$-4M$-12M·
Profitability 8
Metric Trend 20252024202320222021202020192018
Gross Margin 75.4%74.6%73.9%73.8%77.8%77.1%77.8%·
Operating Margin 8.3%3.4%-15.6%-46.7%-16.9%-21.9%-36.7%·
Net Margin 14.5%7.1%-13.2%-49.1%-21.8%-24.4%-44.7%·
Pretax Margin 14.8%8.4%-12.4%-48.0%-21.6%-23.3%-42.9%·
EBITDA Margin 8.3%3.4%-15.6%-46.7%-16.9%-21.9%-36.7%·
ROA 7.3%3.7%-6.6%-19.0%-11.8%-14.8%-33.1%·
ROE 11.2%5.6%-9.7%-26.0%-16.8%-24.6%-66.3%·
ROIC 5.8%1.9%-12.7%-28.6%-8.8%-25.7%-36.5%·
Liquidity & Solvency 3
Metric Trend 20252024202320222021202020192018
Current Ratio 3.75.25.77.17.23.64.3·
Quick Ratio 3.0·1.15.81.92.53.2·
Interest Coverage 2.00.94.3-36.1-3.5-15.1-5.9·
Efficiency 2
Metric Trend 20252024202320222021202020192018
Asset Turnover 0.50.50.50.40.50.60.7·
Inventory Turnover 2.32.62.23.7····
Per Share 1
Metric Trend 20252024202320222021202020192018
EPS (TTM) $0.18$0.05$-0.13$-0.40$-0.21···
Valuation (TTM) 4
Metric Trend 20252024202320222021202020192018
Revenue TTM $52M$41M$32M$27M$30M$22M$23M·
Net Income TTM $8M$3M$-4M$-13M$-6M$-5M$-10M·
P/E 105.7188.6-49.8-6.2-36.7···
Earnings Yield 0.95%0.53%-2.0%-16.2%-2.7%···

Most recent period on the left · null values shown as ·

Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years

16
Metric 2025-12-312024-12-312023-12-312022-12-312021-12-31
Revenue $52M $41M $32M $27M $30M
Gross Margin % 75.4% 74.6% 73.9% 73.8% 77.8%
Operating Margin % 8.3% 3.4% -15.6% -46.7% -16.9%
Net Income $8M $3M $-4M $-13M $-6M
Diluted EPS $0.18 $0.05 $-0.13 $-0.40 $-0.21

Institutional owners (13F) 56 filers · $160.8M total · As of June 30, 2026

17

Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.

Holders 56
Value held $160.8M
New positions 8
Exited positions 8
Institutional activity — Q2 2026 vs prior quarter
New positions Exited positions Increased Decreased Net shares change
8 (-12 vs prior Q) 8 (+1 vs prior Q) 13 (-18 vs prior Q) 19 (+16 vs prior Q) -375K

Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.

Institution Value Shares % of tracked 13F Type
Valor Management LLC $82,434,875 5,314,950 51.27% Shares
MASTERS CAPITAL MANAGEMENT LLC $23,265,000 1,500,000 14.47% Shares
ESSEX INVESTMENT MANAGEMENT CO LLC $9,191,319 592,606 5.72% Shares
RENAISSANCE TECHNOLOGIES LLC $7,381,519 475,920 4.59% Shares
Cresset Asset Management, LLC $4,884,471 314,924 3.04% Shares
Y.D. More Investments Ltd $3,682,586 237,433 2.29% Shares
MORGAN STANLEY $2,930,893 188,968 1.82% Shares
EAGLE GLOBAL ADVISORS LLC $2,832,219 182,606 1.76% Shares
ARK Investment Management LLC $2,210,175 142,500 1.37% Shares
SEI INVESTMENTS CO $1,856,811 119,717 1.15% Shares
UBS Group AG $1,567,704 101,077 0.98% Shares
Sigma Planning Corp $1,557,747 100,435 0.97% Shares
TWO SIGMA INVESTMENTS, LP $1,543,943 99,545 0.96% Shares
ROYCE & ASSOCIATES LP $1,504,982 97,033 0.94% Shares
JPMORGAN CHASE & CO $1,468,562 96,807 0.91% Shares
TWO SIGMA ADVISERS, LP $1,460,736 76,800 0.91% Shares
GOLDMAN SACHS GROUP INC $1,428,331 92,091 0.89% Shares
Huntleigh Advisors, Inc. $1,354,120 87,306 0.84% Shares
Quadrature Capital Ltd $978,588 63,094 0.61% Shares
WELLS FARGO & COMPANY/MN $862,806 55,629 0.54% Shares
CITADEL ADVISORS LLC $737,020 47,519 0.46% Shares
State of Wyoming $600,935 38,745 0.37% Shares
RHUMBLINE ADVISERS $581,753 37,509 0.36% Shares
Trexquant Investment LP $572,195 36,892 0.36% Shares
Man Group plc $426,122 27,474 0.27% Shares
Crossmark Global Holdings, Inc. $393,194 25,351 0.24% Shares
Voleon Capital Management LP $384,819 24,811 0.24% Shares
Good Life Advisors, LLC $360,310 27,400 0.22% Shares
NewEdge Advisors, LLC $292,055 18,830 0.18% Shares
COMMONWEALTH OF PENNSYLVANIA PUBLIC SCHOOL EMPLS RETRMT SYS $270,960 17,470 0.17% Shares
Engineers Gate Manager LP $267,610 17,254 0.17% Shares
SUSQUEHANNA INTERNATIONAL GROUP, LLP $255,729 16,488 0.16% Shares
ROYAL BANK OF CANADA $232,000 14,940 0.14% Shares
Aquatic Capital Management LLC $224,709 14,488 0.14% Shares
GEODE CAPITAL MANAGEMENT, LLC $212,564 13,705 0.13% Shares
CITADEL ADVISORS LLC $170,610 11,000 0.11% Call option
State of Tennessee, Department of Treasury $136,675 8,812 0.09% Shares
OSAIC HOLDINGS, INC. $70,848 4,568 0.04% Shares
GAMMA Investing LLC $56,363 3,634 0.04% Shares
BlackRock, Inc. $26,119 1,684 0.02% Shares
BARCLAYS PLC $22,257 1,435 0.01% Shares
TD Waterhouse Canada Inc. $21,765 1,430 0.01% Shares
LANARK FINANCIAL, INC. $17,061 1,100 0.01% Shares
ACADIAN ASSET MANAGEMENT LLC $12,514 807,931 0.01% Shares
Basepoint Wealth LLC $9,306 600 0.01% Shares
Russell Investments Group, Ltd. $6,049 390 0.00% Shares
NISA INVESTMENT ADVISORS, LLC $5,196 335 0.00% Shares
JONES FINANCIAL COMPANIES LLLP $2,679 185 0.00% Shares
Stone House Investment Management, LLC $2,032 131 0.00% Shares
Steigerwald, Gordon & Koch Inc. $1,861 120 0.00% Shares

Show all 56 institutional owners →

Activists & 5%+ owners 1 position

18

Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.

Filer Filed Stake Status Purpose Filing
Valor BrainsWay Holdings, LLC, Valor Siren Ventures II L.P., Valor Siren Partners II-A L.P., Valor Siren Partners II-B L.P., Valor SV Associates II L.P., Valor SV Capital II LLC, Valor Management L.P., Valor Management LLC, Valor Funds Group LLC, Jonathan Shulkin, Antonio Gracias ×3 filings Oct. 8, 2025 15.00% Amendment · SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Company insiders 3 insiders · 2 officers · 1 directors

19
Insider Role Last activity Shares owned Buys 12m Sells 12m Net 12m
Yiftach Roth Chief Scientist June 2, 2026 S 1,072,305 0 0 $0
Gilad Moiseyev Chief Technology Officer May 25, 2026 M 53,098 0 0 $0
Rayten Michal Ety Mitrany Director May 26, 2026 S 12,500 0 0 $0

Insiders from SEC Form 3/4/5 filings; net = open-market P/S only

ETF ownership Held by 3 ETFs

20

Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.

Fund Weight Units As of Source
IZRL · ARK ETF Trust 1.63% 146,850 NS July 31, 2026 N-PORT
IBRN · iShares Trust 0.43% 2,298 SH Sept. 11, 2026 Daily
ISCF · iShares Trust 0.02% 8,610 SH Sept. 11, 2026 Daily

BWAY Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside

21
rating · 7 analysts BUY
Median target $19.00 +52.0%
3 42.9% Strong Buy
3 42.9% Buy
1 14.3% Hold
0 0.0% Sell
0 0.0% Strong Sell

12-Month Price Target

3 analysts · 2026-10-03

Mean target $19.27 +54.1%

← Below all targets Current price $12.50
Low$18.80 Mean$19.27 High$20.00

Peer comparison (GICS sub-industry) Key metrics vs sector peers

22

FY basis, prices as of each company's last fiscal year-end close.

Ticker Market Cap P/E Rev YoY Net Margin ROE Gross Margin
BWAY · 105.7 · 14.5% 11.2% 75.4%
DRTS $436M -9.3 · · -61.0% ·
INMD $931M 10.3 · 25.3% 13.5% 78.5%
QTEX · · · · · ·
MBAI $11M 2.5 · · 416.7% ·

My Metrics Your personal watchlist — selected rows from Full Fundamentals

26

Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.

Your selection is saved and follows you across all tickers.

Source: SEC 20-F filed Apr 20, 2026